Guangzhou Yinming Biomedical Technology
PrivateLast Round
Private Equity
Jul 8, 2022
Est. Valuation
$616M
Total Funding Raised
$129.4M
Company Overview
Guangzhou Yinming Biomedical Technology operates in Healthcare & Life Sciences and is based in Guangzhou. Its latest recorded funding round was a Private Equity round in July 2022.
Guangzhou Yinming Biomedical Technology is a biotechnology company that develops pharmaceutical drugs, including ophthalmic medications, recombinant botulinum toxins, immuno-oncology therapies, and veterinary immune drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Guangzhou Yinming Biomedical Technology Comparables
Compare Guangzhou Yinming Biomedical Technology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fosun Pharma | 75% | |
| Arctic Vision | 46% | |
| VivaVision Biotech | 37% |
For institutional investors. Book with your work email.
Guangzhou Yinming Biomedical Technology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Jul 8, 2022 | ||||
| Series A Extension | Sep 13, 2021 | ||||
| Series A | Mar 17, 2021 |
For institutional investors. Book with your work email.
Guangzhou Yinming Biomedical Technology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fosun RZ Capital | Series A Extension |
| JCP Capital | Series A |
| Oceanpine Capital | Series A Extension |
| Huajin Capital | Series A, Series A Extension |
| Lightspeed China Partners | Series A |
| Tiger Jade Capital | Series A Extension |
| Flower City Ventures | Series A, Series A Extension |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 13, 2026
Ming Med presents highly positive Phase II data for oral QA102 at the ARVO 2026 Annual Meeting in May '26, showing reduced geographic atrophy progression and preserved visual acuity in intermediate AMD.
For institutional investors. Book with your work email.
Guangzhou Yinming Biomedical Technology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Guangzhou Yinming Biomedical Technology's valuation, stock price, and market status.
Is Guangzhou Yinming Biomedical Technology a public or private company?
Guangzhou Yinming Biomedical Technology is a private company.
What is the current stock price of Guangzhou Yinming Biomedical Technology?
Guangzhou Yinming Biomedical Technology is a private company, so its shares have no public market price. Caplight tracks Guangzhou Yinming Biomedical Technology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Guangzhou Yinming Biomedical Technology worth (valuation)?
Guangzhou Yinming Biomedical Technology's valuation is estimated at $616.0M based on funding round data.
Can I buy Guangzhou Yinming Biomedical Technology stock?
Guangzhou Yinming Biomedical Technology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Guangzhou Yinming Biomedical Technology's last funding round?
Guangzhou Yinming Biomedical Technology's most recent funding round was Private Equity on July 8, 2022.
Who are the main investors in Guangzhou Yinming Biomedical Technology?
Key investors in Guangzhou Yinming Biomedical Technology include Gaorong Capital.
Will Guangzhou Yinming Biomedical Technology IPO soon?
No public IPO plans have been announced for Guangzhou Yinming Biomedical Technology.
How can I track Guangzhou Yinming Biomedical Technology secondary market activity?
Caplight tracks bids, offers, and trades in Guangzhou Yinming Biomedical Technology's shares on secondary markets.